Search Results

Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran).

Novartis Pharmaceuticals Canada Inc. is pleased to announce a partnership with Clarius Mobile Health as part of a dedicated effort to aid in early detection of psoriatic arthritis in Canada.

The closures follow Novartis’s acquisition of MorphyoSys earlier this year.

Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Health Canada has granted Cosentyx® (secukinumab) with a Notice of Compliance (NOC) for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy – representing a safe and efficacious new treatment option for Canadians living with the condition.

Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024.

Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.